EXHIBIT 99.1 Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open Early exercise of common stock warrants by stockholders provid ...

Core Insights - Corvus Pharmaceuticals reported favorable safety and efficacy data for soquelitinib in atopic dermatitis, showing earlier and deeper responses in cohort 3 compared to cohorts 1 and 2 [1][6] - The company is advancing multiple clinical trials for soquelitinib, including a Phase 3 trial for peripheral T cell lymphoma (PTCL) and a Phase 2 trial for autoimmune lymphoproliferative syndrome (ALPS) [2][5] - Corvus raised approximately $31.3 million through the early exercise of common stock warrants by stockholders [1][10] Business Update and Strategy - Soquelitinib is positioned as a potential new treatment for atopic dermatitis and other immune diseases, with ongoing clinical trials and data expected in the fourth quarter [2][3] - The Phase 3 trial for PTCL is enrolling patients at multiple sites, aiming for a total of 150 participants [5][7] - The company is also developing next-generation ITK inhibitors for specific immunology indications [6] Financial Results - As of March 31, 2025, Corvus had cash, cash equivalents, and marketable securities totaling $44.2 million, down from $52.0 million at the end of 2024 [10][29] - Research and development expenses for Q1 2025 were $7.5 million, an increase from $4.1 million in Q1 2024, primarily due to higher clinical trial costs [11] - The net income for Q1 2025 was $15.2 million, including a gain of $25.1 million from changes in the fair value of the company's warrant liability [12][26]

Core Insights - Corvus Pharmaceuticals announced new interim data from a Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis, showing a favorable safety and efficacy profile with earlier and deeper responses in cohort 3 compared to cohorts 1 and 2 [1][2][3] Group 1: Clinical Trial Data - The Phase 1 trial included 48 patients, with 32 receiving soquelitinib and 12 receiving placebo, demonstrating significant responses in EASI 75 and IGA 0 or 1 endpoints [3][4] - The percent reduction in mean EASI scores at 28 days was 54.6% for cohorts 1 and 2 combined and 71.1% for cohort 3, compared to 30.6% and 42.1% for placebo, respectively [7][9] - All cohorts showed significant separation from placebo, with the combined soquelitinib treatment group being significantly superior at day 28 (p=0.03) [9][10] Group 2: Safety and Efficacy - Soquelitinib was well tolerated, with no dose-limiting toxicities and only one treatment-related adverse event reported [15] - Biomarker studies indicated reductions in inflammatory cytokines and an increase in T regulatory cells, supporting the drug's mechanism of action [16] Group 3: Future Directions - The trial protocol has been amended to include an additional 24 patients at the 200 mg twice per day dose for an extended treatment period of 8 weeks, aiming to evaluate stronger efficacy [2][18] - The company plans to initiate a Phase 2 trial before the end of the year based on the interim results [2][18] Group 4: Presentation and Communication - Data from the trial will be presented at the Society for Investigative Dermatology 2025 Annual Meeting, with details shared during the company's first quarter 2025 business update conference call [21][22]

Core Insights - Corvus Pharmaceuticals announced new interim data from a Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis, which will be presented at the Society for Investigative Dermatology 2025 Annual Meeting [1][2] - The company will discuss this data during its first quarter 2025 business update conference call scheduled for May 8, 2025 [1][3] Presentation Details - The presentation titled "Selective Soquelitinib, a selective ITK inhibitor demonstrates activity in atopic dermatitis phase 1 clinical trial by a novel mechanism of action" will be delivered by Dr. Albert S. Chiou [2] - The poster presentation is set for May 8, 2025, from 4:30 – 6:00 pm PT, while the oral presentation will occur on May 10, 2025, from 9:50 – 10:00 am PT [2] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ITK inhibition as a novel immunotherapy approach for various cancers and immune diseases [4] - The lead product candidate, soquelitinib, is an investigational oral small molecule drug that selectively inhibits ITK, with other candidates in development for different cancer indications [4]

Core Insights - Corvus Pharmaceuticals has appointed Richard van den Broek to its board of directors, bringing over 30 years of experience in the life sciences industry [1][2] - The company is focused on advancing ITK inhibition as a novel approach to immunotherapy for various cancers and immune diseases [3] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing ITK inhibition, with its lead product candidate being soquelitinib, an investigational oral small molecule drug [3] - The company is also working on other clinical-stage candidates targeting a range of cancer indications [3] Leadership Experience - Richard van den Broek has a strong background in biotechnology, having previously served on the board of Pharmacyclics, where he contributed to the development of the first BTK inhibitor for lymphomas and immune diseases [2] - He is currently the managing partner at HSMR Advisors and has held directorships at Pulse Biosciences and Cogstate [2]

Corvus Pharmaceuticals (NASDAQ: CRVS ) is essentially a biopharmaceutical company that develops treatments for autoimmune conditions and cancer. Their leading candidate is Soquelitinib, an ITK inhibitor with anti-inflammatory and anti-tumor properties. Soquelitinib can be used forMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, ...

Over the last nine months since we last took a look at them, plucky little startup pharma Corvus Pharmaceuticals (NASDAQ: CRVS ) has been plugging along, releasing fresh rounds of data, business and clinical, that sent theHello! We're Derek and Betsy, a husband-and-wife investment duo. Our experiences include academia, fintech, software engineering, manufacturing and corporate finance. We're value investors who know our circle of competence and have a healthy appreciation for macroeconomic trends. We're als ...

Financial Data and Key Metrics Changes - Research and development (R&D) expenses in Q4 2024 were $5.2 million, up from $3.2 million in Q4 2023, primarily due to increased clinical trial expenses for socalitinib [6] - Full year R&D expenses for 2024 totaled $19.4 million, compared to $16.5 million in 2023, reflecting an increase of approximately $2.9 million [7] - The net loss for Q4 2024 was $12.1 million, compared to a net loss of $6.7 million in Q4 2023 [8] - Total stock compensation expense for Q4 2024 was $0.8 million, compared to $0.6 million in Q4 2023 [8] - As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $52 million, up from $27.1 million at the end of 2023 [9] Business Line Data and Key Metrics Changes - Socalitinib showed a 39% objective response rate in the Phase 1 trial for relapsed T-cell lymphoma, with a 26% complete response rate, significantly higher than standard chemotherapies [12] - Interim data from the Phase 1 trial of socalitinib in moderate to severe atopic dermatitis indicated significant responses compared to placebo [13] Market Data and Key Metrics Changes - The company is enrolling a registrational Phase 3 trial of socalitinib in patients with relapsed peripheral T-cell lymphoma [12] - The Phase 1 trial for atopic dermatitis includes four cohorts, with a total of 16 subjects each, showing promising efficacy results [15][19] Company Strategy and Development Direction - The company aims to position socalitinib as a first-in-class oral therapy for immune diseases and cancer, leveraging its unique mechanism of action [11] - Plans include advancing multiple clinical trials for socalitinib, including a Phase 2 trial in solid tumors and a Phase 2 trial in atopic dermatitis [29][32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of socalitinib, citing a strong body of evidence from clinical and preclinical research [11] - The company anticipates its cash runway will extend into the first quarter of 2026, allowing for the execution of key milestones [10][33] Other Important Information - The company is also advancing other clinical stage development programs, including adenosine A2A receptor antagonists for cancer treatment [30] - The ALPS trial is being conducted under a clinical research agreement with the NIH, targeting a rare autoimmune disease with a patient population of approximately 2,500 in the U.S. [68] Q&A Session Summary Question: Will the May update include full data on cohorts three and additional patients on cohort two? - Management confirmed that the May meeting will report full datasets on cohorts one, two, and three, including biomarker data [38] Question: What efficacy hurdles are being considered for the Phase 2a trial? - Management indicated satisfaction with the efficacy seen in cohorts one and two, noting a significant difference compared to placebo [41][44] Question: What are the plans for cohort four and the rationale for dosing? - Management stated that cohort four is planned at a 400 mg dose, pending review of cohort three data [50][52] Question: What is the addressable patient population for the ALPS indication? - Management noted approximately 2,500 patients in the U.S. with ALPS, emphasizing the potential for long-term treatment [68] Question: What subpopulations are being targeted in the upcoming Phase 2 for atopic dermatitis? - Management indicated that the focus will be on patients with moderate to severe atopic dermatitis who have failed prior treatments [76]

Corvus Pharmaceuticals (CRVS) Q4 2024 Earnings Call March 26, 2025 12:20 AM ET Company Participants Zack Kubow - Managing DirectorLeiv Lea - Chief Financial OfficerRichard Miller - Co-Founder, President, CEO & Chairman of the BoardCha Cha Yang - Senior Associate, Biotech Equity ResearchSean Lee - VP - Equity Research Conference Call Participants Jeff Jones - Managing Director - Senior AnalystDaniel Browder - Analyst Operator Good afternoon, everyone. Thank you for standing by, and welcome to the Corvus Phar ...

Corvus Pharmaceuticals, Inc. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Delaware 001-37719 46-4670809 (State or other jurisdiction of incorporation) (Commission Fil ...